Greg Ambra, MS, CEO
Greg Ambra has 20 years of experience in the clinical research industry, having held strategic leadership positions in industry-leading sponsor and CRO companies. Serving as CEO of DZS Clinical Services since its acquisition by WDB Holdings in 2018, Ambra has continued to foster a culture of excellence, sense of urgency and a sincere desire to mentor and grow future leaders in the industry. As a result, Ambra has led the organization through various multinational drug and device development programs, many of which resulted in successful regulatory approvals and significant commercial success.
Prior to assuming the role of CEO, Ambra led DZS Clinical Services as both president and vice president of clinical operations from 2012 to 2018. This was shortly after the boutique CRO he founded (InQuiry Research), which provided data analytics and clinical development services to small and midsized companies, was successfully sold to DZS Software Solutions, the developer of a proprietary clinical trials software. The acquisition led to the expansion of services to include full-service clinical development activities and clinical staffing. DZS Clinical Services went on to support over 80 clinical development projects in that time period, with many resulting in successful drug and device regulatory submissions in the US, EU and China and in the MENA region.
DZS Clinical Services has achieved consistent growth and expansion throughout his tenure and continues to grow the list of clients it serves. As president, Ambra was part of the management team that executed the successful sale of the company’s software platform in 2017 and has overseen significant top-line revenue growth over a four-year period leading to the successful acquisition by WDB Medical Group in 2018.
Education and Memberships
- BA, History, Hofstra University, Hempstead, NY, Dean’s List, NCAA “Scholar/Athlete Award” (2002)
- MS, Medical Sciences, Boston University, Boston, MA, Thesis Honors (1999)